Predict your next investment

Corporation
HEALTHCARE | Pharmaceuticals / Drugs
tevapharm.com

See what CB Insights has to offer

Investments

15

Portfolio Exits

12

Partners & Customers

10

About Teva Pharmaceuticals

Teva Pharmaceutical Industries, headquartered in Israel, is a generic pharmaceutical company. Teva develops, manufactures and markets generic and innovative human pharmaceuticals and active pharmaceutical ingredients.

Teva Pharmaceuticals Headquarter Location

5 Basel St.

Petah Tikva, 49131,

Israel

+972-3-9267267

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Teva Pharmaceuticals

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find Teva Pharmaceuticals in 4 Expert Collections, including Pharma Startups.

P

Pharma Startups

11,639 items

Pharmaceutical companies working across drug discovery, drug development and drug manufacturing.

I

Infectious Disease

2,226 items

Entities aiding the surveillance, screening, prevention, diagnosis, treatment, and containment of infections & the maintenance of public wellbeing during outbreaks.

C

Conference Exhibitors

5,302 items

M

Medical Devices

297 items

Companies that received PMA from the FDA since 2014. Companies tagged as #FDAPMA

Teva Pharmaceuticals Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Teva Pharmaceuticals Rank

Research containing Teva Pharmaceuticals

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Teva Pharmaceuticals in 2 CB Insights research briefs, most recently on Apr 19, 2021.

Latest Teva Pharmaceuticals News

Federal Circuit Vacates Judgment, Reinstates Jury's Verdict of Induced Infringement

Sep 22, 2021

To embed, copy and paste the code into your website or blog: <iframe frameborder="1" height="620" scrolling="auto" src="//www.jdsupra.com/post/contentViewerEmbed.aspx?fid=dddb611c-425e-4856-86e8-d236ef59f442" style="border: 2px solid #ccc; overflow-x:hidden !important; overflow:hidden;" width="100%"></iframe> In Short The Situation: The Hatch-Waxman Act allows generic drug companies to omit from their labeling approved indications that are covered by the innovator's patents. While these "skinny labels" can be used to support a noninfringement defense, in GlaxoSmithKline v. Teva Pharmaceuticals, the Federal Circuit considered whether Teva's generic version of GSK's COREG® induced infringement despite Teva omitting from its label the indication for treatment of heart failure, which was claimed in a GSK patent. The Result: On August 5, 2021, the U.S. Court of Appeals for the Federal Circuit ruled that substantial evidence supported the conclusion that Teva induced infringement of GSK's patent even during the time period when Teva used a "skinny label," or Section viii carve-out, that omitted the heart failure indication. The Federal Circuit found Teva's conduct in marketing and advertising the generic drug sufficient to establish inducement despite the skinny label. Looking Ahead: Although this decision is unlikely to impact the analysis of "skinny labels" in a pre-marketing context, once a generic drug is launched, innovator companies should pay attention to how the generic advertises and markets the product, as this evidence—including any statements regarding therapeutic equivalency to the innovator product—may be sufficient to establish induced infringement even with a Section viii carve-out Background On August 5, 2021, the Federal Circuit issued an opinion in GlaxoSmithKline v. Teva Pharmaceuticals, Case No. 18-1976, in favor of GSK, finding that Teva was liable for inducing infringement of GSK's patent. This decision reversed the grant of judgment as a matter of law ("JMOL") that was entered by the trial court below and reinstated the jury's verdict for GSK. The case involved so-called "skinny labels," also known as Section viii carve-outs—a reference to the provision of the Hatch-Waxman Act that allows a generic company to vary the label of its products from that of the reference listed drug in order to exclude one or more indications that are patented by the innovator. In this case, Teva sought and obtained FDA approval of a generic version of GSK's COREG® product but carved out of its label the approved indication for treatment of heart failure, in order to avoid a GSK patent claiming this use. Years after the product was launched with the "skinny label," the FDA ordered Teva to add the heart failure indication back into its label. GSK brought a suit for patent infringement, claiming that Teva was liable for inducing infringement of its patent even during the time period when Teva's label omitted the heart failure indication. GSK argued that Teva's label was ambiguous, and further that Teva's conduct in the actual marketing and advertising of its generic drug was sufficient to establish inducement under 35 U.S.C. § 271(b). The jury agreed with GSK, but the trial judge granted Teva's motion for JMOL, finding as a matter of law that Teva could not have induced infringement because it had specifically availed itself of the Section viii carve-out procedure and had removed the patented indication from its label. GSK appealed, and in October 2020, the Federal Circuit reversed and reinstated the jury verdict, based largely on Teva's promotional materials, which advertised its generic as therapeutically equivalent to GSK's COREG®. In February 2021, the panel granted Teva's motion for rehearing, vacated its opinion, and scheduled new oral argument to address infringement during the skinny-label period. Opinion of August 5, 2021 In a 2–1 opinion, the panel again concluded that the "narrow, case-specific review of substantial evidence" supported the jury's verdict of induced infringement by Teva. Similar to its October 2020 opinion, the panel determined that Teva's marketing and promotional materials showed evidence of intent to induce infringement, even during the time when its label did not include the heart failure indication. It found that Teva could have advertised its drug as a cardiovascular agent, leaving physicians to wonder about its indications, but instead took affirmative steps via press releases to market its generic as an "AB-rated equivalent" of COREG®. This, according to the panel, was "Teva in a press release telling the world that its generic is a substitute for GSK's COREG®" for all approved indications, regardless of what Teva's more narrow label said, and it was reasonable for the jury to conclude as much. Unlike the October 2020 opinion, however, the panel's second decision also included discussion of the indications remaining (i.e., not carved out) in Teva's label. While Teva carved out the patented indication for the "treatment of heart failure," it did not carve out the indication for the treatment of post-myocardial infarction left ventricular dysfunction ("post-MI LVD"). GSK's expert testified that treating post-MI LVD patients overlapped with treating heart failure patients, meaning Teva's carve-out was not a "skinny label" but, rather, a "partial label." The court agreed with GSK. It said Teva failed to challenge the testimony of GSK's expert, and even Teva's own expert admitted some overlap did exist. The court also clarified that infringement via overlapping indications was a factual issue for the jury to decide, not a legal one for the district court to review de novo. Recap This case highlights the unsettled and contentious nature of infringement in the skinny-label context. The decision indicates that the use of a skinny label is not a dispositive noninfringement argument, at least after the product has been launched; courts can consider all evidence, including the label, expert testimony, and marketing and promotional materials to assess infringement. This was a post-marketing case, so questions remain concerning how it will be applied to "standard" Hatch-Waxman cases where infringement issues are addressed prior to FDA approval and launch of a generic. Three Key Takeaways Using Hatch-Waxman's Section viii carve-out procedure alone may not be enough to avoid a finding of infringement, at least in the post-marketing context. Indications on a generic's label coupled with marketing materials and press releases advertising the generic's drug as the AB-rated equivalent of the brand can be sufficient to show infringement. The court's decision to vacate its October 2020 opinion and reissue a new opinion reaching the same conclusion suggests an attempt to narrow its holding to the unique facts of this case.

Teva Pharmaceuticals Investments

15 Investments

Teva Pharmaceuticals has made 15 investments. Their latest investment was in Remedix as part of their Corporate Minority - II on September 9, 2019.

CBI Logo

Teva Pharmaceuticals Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

9/9/2019

Corporate Minority - II

Remedix

Yes

1

5/18/2017

Corporate Minority

Heptares Therapeutics

$5M

Yes

2

6/18/2015

Corporate Minority - II

Keratin Biosciences

$35M

Yes

1

6/2/2015

Corporate Minority

Subscribe to see more

$99M

Subscribe to see more

10

5/15/2012

Series E

Subscribe to see more

$99M

Subscribe to see more

10

Date

9/9/2019

5/18/2017

6/18/2015

6/2/2015

5/15/2012

Round

Corporate Minority - II

Corporate Minority

Corporate Minority - II

Corporate Minority

Series E

Company

Remedix

Heptares Therapeutics

Keratin Biosciences

Subscribe to see more

Subscribe to see more

Amount

$5M

$35M

$99M

$99M

New?

Yes

Yes

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

1

2

1

10

10

Teva Pharmaceuticals Portfolio Exits

12 Portfolio Exits

Teva Pharmaceuticals has 12 portfolio exits. Their latest portfolio exit was Immuneering on July 30, 2021.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

7/30/2021

IPO

$991

1

9/17/2020

IPO

$991

11

10/26/2018

IPO

$991

4

00/00/0000

Subscribe to see more

Subscribe to see more

$991

Subscribe to see more

10

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

Date

7/30/2021

9/17/2020

10/26/2018

00/00/0000

00/00/0000

Exit

IPO

IPO

IPO

Subscribe to see more

Subscribe to see more

Companies

Subscribe to see more

Subscribe to see more

Valuation

$991

$991

$991

$991

Acquirer

Subscribe to see more

Subscribe to see more

Sources

1

11

4

10

10

Teva Pharmaceuticals Acquisitions

15 Acquisitions

Teva Pharmaceuticals acquired 15 companies. Their latest acquisition was Allergan - Anda Distribution Business on August 05, 2016.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

8/5/2016

$991

Acquired Unit

1

8/2/2016

$991

Acquired Unit

4

7/27/2016

$991

Acquired Unit

4

10/1/2015

Subscribe to see more

$991

$99M

Subscribe to see more

10

9/25/2015

Subscribe to see more

$99M

Subscribe to see more

10

Date

8/5/2016

8/2/2016

7/27/2016

10/1/2015

9/25/2015

Investment Stage

Companies

Subscribe to see more

Subscribe to see more

Valuation

$991

$991

$991

$991

Total Funding

$99M

$99M

Note

Acquired Unit

Acquired Unit

Acquired Unit

Subscribe to see more

Subscribe to see more

Sources

1

4

4

10

10

Teva Pharmaceuticals Partners & Customers

10 Partners and customers

Teva Pharmaceuticals has 10 strategic partners and customers. Teva Pharmaceuticals recently partnered with Alvotech on August 8, 2020.

Date

Type

Business Partner

Country

News Snippet

Sources

8/5/2020

Partner

Alvotech

Iceland

Teva and Alvotech Announce Strategic Partnership to Collaborate in the U.S. Biosimilar Market

This strategic partnership combines Teva 's long-standing commercial presence and extensive infrastructure in the U.S. market with Alvotech 's scientific experience and state-of-the-art biologics manufacturing .

4

2/21/2020

Partner

Direct Relief

United States

Advancing Access to Essential Medicines. By Teva Pharmaceutical Industries Ltd. 7 minutes.

On International Childhood Cancer Day , we announced our donation partnership with Global HOPE , a program of Texas Children 's Hospital , and Direct Relief , a leading humanitarian aid organization that is active in more than 80 countries around the world .

1

11/26/2019

Partner

Tel Aviv University

Israel

Teva forms academic R&D pacts to further biopharma strategy

That work has now manifested in strategic collaborations such as the partnerships with the Weizmann Institute of Science and Tel Aviv University .

2

11/25/2019

Partner

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

11/7/2019

Licensor

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

Date

8/5/2020

2/21/2020

11/26/2019

11/25/2019

11/7/2019

Type

Partner

Partner

Partner

Partner

Licensor

Business Partner

Alvotech

Direct Relief

Tel Aviv University

Country

Iceland

United States

Israel

Subscribe to see more

Subscribe to see more

News Snippet

Teva and Alvotech Announce Strategic Partnership to Collaborate in the U.S. Biosimilar Market

This strategic partnership combines Teva 's long-standing commercial presence and extensive infrastructure in the U.S. market with Alvotech 's scientific experience and state-of-the-art biologics manufacturing .

Advancing Access to Essential Medicines. By Teva Pharmaceutical Industries Ltd. 7 minutes.

On International Childhood Cancer Day , we announced our donation partnership with Global HOPE , a program of Texas Children 's Hospital , and Direct Relief , a leading humanitarian aid organization that is active in more than 80 countries around the world .

Teva forms academic R&D pacts to further biopharma strategy

That work has now manifested in strategic collaborations such as the partnerships with the Weizmann Institute of Science and Tel Aviv University .

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

4

1

2

10

10

Teva Pharmaceuticals Team

50 Team Members

Teva Pharmaceuticals has 50 team members, including current President, Mike Netz.

Name

Work History

Title

Status

Mike Netz

President

Current

Dov Primovitch

Chief Financial Officer

Current

Dan Suesskind

Chief Financial Officer

Current

Yoram Ilan

Senior Director

Current

Dr Jeremy M Levin

Chief Executive Officer, President

Former

Name

Mike Netz

Dov Primovitch

Dan Suesskind

Yoram Ilan

Dr Jeremy M Levin

Work History

Title

President

Chief Financial Officer

Chief Financial Officer

Senior Director

Chief Executive Officer, President

Status

Current

Current

Current

Current

Former

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.